• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对于舌癌复发性颈淋巴结转移患者，在使用纳武单抗治疗进展后成功再次使用西妥昔单抗治疗。

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue.

作者信息

Asada Yasuyuki, Teramura Chitoshi, Wada Takuma, Machida Yoshisato, Koshinuma Shinya, Yamamoto Gaku

机构信息

Department of Oral and Maxillofacial Surgery Shiga University of Medical Science Shiga Japan.

Department of Oral and Maxillofacial Surgery Otsu City Hospital Shiga Japan.

出版信息

Clin Case Rep. 2021 Jul 16;9(7):e04464. doi: 10.1002/ccr3.4464. eCollection 2021 Jul.

DOI:10.1002/ccr3.4464
PMID:34295486
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8283856/
Abstract

We can infer that the immunostimulatory effect of nivolumab and reactivation of cetuximab enhance the antitumor effect of the therapy.

摘要

我们可以推断，纳武单抗的免疫刺激作用和西妥昔单抗的再激活增强了该疗法的抗肿瘤效果。

相似文献

1
Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue.对于舌癌复发性颈淋巴结转移患者，在使用纳武单抗治疗进展后成功再次使用西妥昔单抗治疗。
Clin Case Rep. 2021 Jul 16;9(7):e04464. doi: 10.1002/ccr3.4464. eCollection 2021 Jul.
2
Complete Response to Cetuximab Plus Paclitaxel Therapy in Nivolumab-Refractory Patients in Distant Metastasis of Squamous Cell Carcinoma of the Tongue: A Report of Two Cases.西妥昔单抗联合紫杉醇治疗对nivolumab难治性远处转移舌鳞状细胞癌患者的完全缓解：两例报告
Cureus. 2023 Nov 21;15(11):e49198. doi: 10.7759/cureus.49198. eCollection 2023 Nov.
3
The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue.抗内皮生长因子受体和抗血管内皮生长因子受体2联合靶向治疗对淋巴结转移的影响：一项在舌鳞状细胞癌原位裸鼠模型中的研究
Arch Otolaryngol Head Neck Surg. 2009 Apr;135(4):411-20. doi: 10.1001/archoto.2009.14.
4
[Characteristics of occult cervical lymph node metastasis in squamous cell carcinoma of tongue and their influence on prognosis].[舌鳞状细胞癌隐匿性颈淋巴结转移的特征及其对预后的影响]
Ai Zheng. 2003 May;22(5):541-4.
5
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.纳武利尤单抗治疗复发和/或转移性头颈部鳞状细胞癌后化疗的疗效
Auris Nasus Larynx. 2020 Feb;47(1):116-122. doi: 10.1016/j.anl.2019.05.001. Epub 2019 May 23.
6
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.纳武利尤单抗治疗复发或转移性头颈部鳞状细胞癌患者：CheckMate 141 研究中既往接受西妥昔单抗治疗患者的疗效和安全性。
Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.
7
Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.在接受依匹单抗/尼伏单抗治疗后，对最初接受派姆单抗治疗时 T-VEC 进展的皮肤恶性黑色素瘤患者进行 Talimogene Laherparepvec（T-VEC）再挑战的反应。
J Immunother. 2019 May;42(4):136-141. doi: 10.1097/CJI.0000000000000265.
8
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.头颈部鳞状细胞癌的当前靶向治疗对肿瘤微环境的修饰。
J Exp Clin Cancer Res. 2023 May 5;42(1):114. doi: 10.1186/s13046-023-02691-4.
9
[The biological properties of VX-2 squamous cell carcinoma model in different sites of rabbit tongue and cervical lymph node metastasis].[VX-2 鳞状细胞癌模型在兔舌不同部位及颈部淋巴结转移的生物学特性]
Shanghai Kou Qiang Yi Xue. 2007 Oct;16(5):497-501.
10
Risk factors for late cervical lymph node metastases in patients with stage I or II carcinoma of the tongue.Ⅰ期或Ⅱ期舌癌患者发生晚期颈淋巴结转移的危险因素。
Head Neck. 2002 Aug;24(8):731-6. doi: 10.1002/hed.10130.

引用本文的文献

1
Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.头颈部鳞状细胞癌的当前靶向治疗对肿瘤微环境的修饰。
J Exp Clin Cancer Res. 2023 May 5;42(1):114. doi: 10.1186/s13046-023-02691-4.

本文引用的文献

1
[Ⅳ.Treatment of Unresectable Cases-Immune Checkpoint Inhibitor].[四、不可切除病例的治疗——免疫检查点抑制剂]
Gan To Kagaku Ryoho. 2020 Jul;47(7):1050-1054.
2
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂治疗后晚期非小细胞肺癌患者接受单药化疗的反应率。
Lung Cancer. 2017 Oct;112:90-95. doi: 10.1016/j.lungcan.2017.07.034. Epub 2017 Aug 3.
3
Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
在接受 PD-1/PD-L1 抑制剂治疗的非小细胞肺癌患者中，挽救性化疗的反应率增加。
J Thorac Oncol. 2018 Jan;13(1):106-111. doi: 10.1016/j.jtho.2017.10.011. Epub 2017 Oct 31.
4
Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.纳武利尤单抗耐药肺癌对挽救性化疗的显著反应。
Thorac Cancer. 2018 Jan;9(1):175-180. doi: 10.1111/1759-7714.12543. Epub 2017 Oct 24.
5
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.一项纳武利尤单抗对比研究者选择的治疗方案用于复发性头颈部鳞状细胞癌的随机、开放标签、III 期临床试验：Checkmate 141 中亚洲患者与全球人群的亚组分析。
Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1.
6
The implications of clonal genome evolution for cancer medicine.克隆基因组进化对癌症医学的影响。
N Engl J Med. 2013 Feb 28;368(9):842-51. doi: 10.1056/NEJMra1204892.
7
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.化疗在体内拓宽了细胞毒性 CD8(+)T 细胞所识别的肿瘤抗原范围。
Cancer Immunol Immunother. 2012 Dec;61(12):2343-56. doi: 10.1007/s00262-012-1307-4. Epub 2012 Jun 20.
8
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?西妥昔单抗在转移性结直肠癌患者中的再挑战：如何克服获得性耐药？
Ann Oncol. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5.
9
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.5-氟尿嘧啶选择性杀死肿瘤相关的髓系来源的抑制性细胞，从而增强 T 细胞依赖性抗肿瘤免疫。
Cancer Res. 2010 Apr 15;70(8):3052-61. doi: 10.1158/0008-5472.CAN-09-3690. Epub 2010 Apr 13.
10
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.非细胞毒性浓度的化疗药物通过白细胞介素-12依赖机制增加树突状细胞的抗原呈递。
J Immunol. 2009 Jul 1;183(1):137-44. doi: 10.4049/jimmunol.0900734. Epub 2009 Jun 17.